Interpace Diagnostics Group, Inc.

About

Delivering Cutting-edge and
Much-needed Molecular Analysis

Interpace Diagnostics Group, Inc. is a fully integrated commercial and bioinformatics company that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services. We develop and commercialize molecular diagnostic tests that deliver cutting-edge genetic and mutational analysis. Our tests help risk-stratify patient samples for thyroid, pancreatic, lung, and other cancers to better inform treatment decisions.

Our Mission

We work to improve patient care through personalized medicine driven by molecular diagnostic tests that are supported by rigorous science. Via our unique molecular diagnostic tests, healthcare providers will be able to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Capabilities that Resolve Diagnostic Uncertainty

Our molecular diagnostic tests leverage the latest technology to deliver accurate results.

  • Predicting outcomes years down the road.
  • Determining whether a tumor is truly benign or malignant.
  • Combining Next Generation Sequencing and a miRNA classifier to deliver favorable positive and negative predictive values.
  • Early disease detection.
  • Multiple prognostic platforms to detect & evaluate the most aggressive cancers and diseases.
  • Using "Integrated Molecular Profiling" to combine clinical, imaging, cytology, serum markers, tumor oncogenes, and LOH to ascribe a risk stratification to each patient
  • Our experienced molecular pathologists provide reports with treatment recommendations and algorithms

As part of its quality procedures Interpace has established a formal Consensus Conference comprised of the Company’s experienced internal molecular pathologists as well as its Key Opinion Leaders across all areas of cancer in which the Company is focused.  This group jointly reviews complicated cases to ensure the most accurate diagnosis and prognosis is reported to the ordering physician.

Reduce Unnecessary Expenses
With Molecular Diagnostics

We believe that Molecular Diagnostic testing represents strong patient value given the substantial opportunity it represents to lower healthcare costs by helping to reduce unnecessary surgeries and ensuring the appropriate frequency of ongoing monitoring that requires additional resources. In the era of high deductible and co-insurance plans, patients are taking on more and more responsibility for their own health care costs. Reducing unnecessary surgeries is another way Interpace's products assist patients.

Patients
Personalized Medicine Through Molecular Diagnostics

Personalized Medicine Through Molecular Diagnostics

Our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. We currently have five commercialized molecular diagnostic tests in the marketplace: PancraGEN®, ThyGeNEXT®, ThyraMIR®, RespriDX™, and BarreGen®.

View Diagnostic Products
State-of-the-art, CLIA-certified Laboratories

State-of-the-art, CLIA-certified Laboratories

All of our testing services are performed in our clinical reference laboratories located in Pittsburgh, Pennsylvania and New Haven, Connecticut, which have Clinical Laboratory Improvement Amendment (CLIA) certification and have been accredited by the College of American Pathologists (CAP).

View Labs

Meet Our Team

Our success is largely attributed to the efforts of members of our skillful leadership team. As we continue to grow our molecular diagnostics business and develop and/or acquire additional molecular diagnostic tests, we will grow ever more reliant on their skills, experience, and performance.

View Management Team View Board of Directors